Originally published In Press as doi:10.1074/jbc.M000918200 on April 10, 2000
J. Biol. Chem., Vol. 275, Issue 24, 18070-18078, June 16, 2000
Glc7p Protein Phosphatase Inhibits Expression of
Glutamine-Fructose-6-phosphate Transaminase from GFA1*
Jianhong
Zheng
,
Miriam
Khalil, and
John F.
Cannon§
From the Department of Molecular Microbiology and Immunology,
University of Missouri, Columbia, Missouri 65212
Received for publication, February 4, 2000, and in revised form, April 6, 2000
 |
ABSTRACT |
Inhibitor-1 (I-1) is a specific inhibitor of
protein phosphatase-1 (PP1). We assayed the ability of I-1 to inhibit
Saccharomyces cerevisiae PP1, Glc7p, in
vivo. Glc7p like other PP1 catalytic subunits associates
with a variety of noncatalytic subunits, and Glc7p holoenzymes perform
distinct physiological roles. Our results show that I-1 inhibits Glc7p
holoenzymes that regulate transcription and mitosis, but holoenzymes
responsible for meiosis and glycogen metabolism were unaffected.
Additionally, we exploited a genetic screen for mutants that were
dependent on I-1 to grow. This scheme can identify processes that are
negatively regulated by Glc7p-catalyzed dephosphorylation. In this
paper I-1-dependent gfa1 mutations were
analyzed in detail. GFA1 encodes
glutamine-fructose-6-phosphate transaminase. One or more phosphorylated
proteins activate GFA1 transcription because the pheromone
response and Pkc1p/mitogen-activated protein kinase pathways positively
regulate GFA1 transcription. Our findings show that an
I-1-sensitive Glc7p holoenzyme reduces GFA1
transcription. Therefore, GFA1 is a member of a
growing list of genes that are negatively regulated by Glc7p dephosphorylation.
 |
INTRODUCTION |
Protein phosphatase-1
(PP1),1 a major eukaryotic
protein serine/threonine phosphatase, regulates a wide variety of
physiological processes, including protein synthesis, cell cycle
progression, carbohydrate metabolism, ion channel regulation, and gene
transcription (1-3). In the budding yeast Saccharomyces
cerevisiae, PP1 is encoded by a single gene GLC7, and
it has >80% identity at amino acid level with its mammalian
counterparts (4, 5). GLC7 is essential for growth and is
involved in multiple physiological processes including glycogen
metabolism, sporulation, cell cycle progression, chromosome
segregation, protein synthesis, and glucose repression (4-9).
Most if not all intracellular PP1 exists in association with
noncatalytic regulatory subunits (1-3). At least nine noncatalytic subunits have been identified in S. cerevisiae by molecular
genetics (10, 11). The holoenzymes pair the single PP1 catalytic
subunit, Glc7p, with alternative noncatalytic subunits. Each Glc7p
holoenzyme is likely to have distinctive functions in vivo.
PP1 noncatalytic subunits dictate substrate dephosphorylation in part
by controlling the subcellular localization of the holoenzyme. The
traits of noncatalytic subunit mutations in S. cerevisiae
have provided preliminary evidence about the physiological processes
regulated by each Glc7p holoenzyme. For example, the Glc7p/Gac1p
holoenzyme regulates glycogen metabolism (12), Glc7p/Sds22p governs
mitosis (13, 14), Glc7p/Gip1p is involved sporulation (11), and Glc7p/Reg1p modulates glucose repression (8). All Glc7p noncatalytic subunits studied to date act positively because mutations in
noncatalytic subunit genes mimic the traits of glc7 loss of
function alleles.
In mammalian cells, endogenous inhibitors, inhibitor-1 (I-1), DARPP-32,
inhibitor-2, ribosomal protein, RIPP-1, and nuclear protein, NIPP-1
also regulate PP1 activity (15-19). The homologous proteins I-1 and
DARPP-32 inhibit PP1 activity via multiple interactions with PP1.
Phosphorylation of threonine 35 in these inhibitors is critical since
they are only functional inhibitors after phosphorylation by
cAMP-dependent protein kinase (16, 20). Additionally, the N-terminal tetrapeptide sequence KIQF of these inhibitors is also required for PP1 inhibition (21, 22). X-ray crystallography data of the
PP1 catalytic subunit bound to a regulatory subunit identified this
tetrapeptide sequence as a recognition motif that is shared by many
PP1-binding proteins (23).
To date, no negative regulators for Glc7p have been identified in
S. cerevisiae. The yeast genome does not encode recognizable homologs to I-1, DARP-32, or NIPP-1. Moreover, Glc8p, which has sequence similarity to inhibitor-2, acts more like a positive regulator
of Glc7p in S. cerevisiae (24, 25). However, Glc7p activity
must be tightly regulated in yeast because great alterations are
detrimental to cell viability. Depletion of Glc7p leads to arrest in
the G1 or M-phase of the cell cycle (7, 25, 26). In
contrast, overexpression of GLC7 causes hyperpolarized
growth and cell death (25-27).
Phosphorylated I-1 is a potent Glc7p inhibitor in vitro
(28). Indeed I-1 inhibition is a defining criteria used to classify protein phosphatases as type 1 protein phosphatases (1-3).
Furthermore, I-1 interacts with Glc7p in vivo (29). In this
study, we tested the ability of human I-1 to inhibit yeast Glc7p
holoenzymes in vivo. Since there are a number of
glc7 traits, some of which can be attributed to specific
holoenzymes, these analyses surveyed the ability of I-1 to inhibit a
spectrum of Glc7p holoenzymes. Our data indicate that I-1 can inhibit
some but not all Glc7p holoenzymes. Finally, we isolated mutants that
required I-1 expression to grow. We found that some gfa1
mutants required I-1 or some other means of Glc7p inhibition to grow. A
thorough analysis revealed that Glc7p activity inhibits transcription
of GFA1. By inhibiting Glc7p activity, GFA1
transcription increased sufficiently in the isolated gfa1
mutants to overcome their glucosamine auxotrophy trait.
 |
EXPERIMENTAL PROCEDURES |
Strains, Media, and Growth Conditions--
Yeast strains CH1305
(MAT
ade2 ade3 leu2 ura3 lys2 can1), JC746-9D
(MATa ura3 leu2 his3 trp1 can1), and JC746
(MATa/MAT
ura3/ura3 leu2/leu2 his3/his3 trp1/trp1
can1/can1) have been described previously (5, 30). JC1053-3D is an
isogenic MATa derivative of CH1305 obtained by
HO-induced mating type conversion. Strains JC1085-18B
(MAT
ura3 his3 trp1 lys2::HIS3
ipl1-1) and JC1117-7D (MATa ura3 leu2 his3 trp1 ipl1-1)
result from serial backcrosses of ipl1-1 strains (6) to
JC746-9D. Yeast were grown in rich YEP-glucose medium or synthetic
medium supplemented with amino acids (31). The alternative carbon
sources, galactose, raffinose, or fructose, replaced glucose in some
media at 2% (w/v). For scoring the colony-sectoring trait, low adenine
synthetic medium was used that contained 6 µg of adenine per ml. For
growing gfa1-97 and gfa1::URA3 strains,
filter-sterilized D-glucosamine was added to rich or
synthetic media at a final concentration between 1 and 5 mg/ml.
YEP-glucose medium with increased osmolarity contained 0.8 M sorbitol or 0.25 M NaCl. Escherichia
coli DH5
(F'/endA1 hsdR17 supE recA1 gyrA relA1
(lacZYA argF) U169
80dlac
(lacZ)M15) was used for recovering
plasmids from yeast transformants and for DNA manipulations.
Plasmid Constructions--
Plasmids used in this work are
summarized in Table I. Plasmid pJZ204 was
constructed by transferring a KpnI-SalI I-1
fragment from plasmid pGEM3Zf-I-1 (22) into the
KpnI and SalI sites of pG-3 (32), placing I-1
under control of the GPD1, glyceraldehyde-3-phosphate dehydrogenase promoter. The SalI-HindIII fragment
from pJZ204 carrying a GPD1 promoter-driven I-1
gene was further subcloned into pTSV30A, pRS316, and pRS426 to
generate pJZ203, pJZ205, and pJZ206 respectively. Cloning the mutant
I-1 (T35A) KpnI-SalI fragment from
pGEM3Zf-I-1-T35A into the pG-3 vector generated plasmid
pJZ207. The SalI-HindIII fragment carrying
GPD1-driven I-1-T35A was further subcloned into pRS316 and
pRS426 to make pJZ208 and pJZ209. Plasmid p2168 was constructed in
several steps. It contains the truncated GLC7 gene from pA26
(9) encoding residues 1-207 of Glc7p in the pRS426 vector.
Plasmid pJZ501 was isolated by complementation of the
gfa1-97 mutation in JC1007-97. Derivatives of pJZ501 were
made to localize the complementing region of DNA. GFA1 is
the only known open reading frame on the gfa1-97
complementing plasmid, pJZ504, that has a 3.7-kilobase pair
EcoRI fragment in pRS316. Integrative plasmids, p2368 and
p2397, contain the YSC1-GFA1 intergenic region
(SalI-EcoRI or SalI-BamHI
fragments) cloned into YIp356 or YIp366, respectively (85), to make
GFA1-lacZ fusions.
Isolation of Mutants That Require I-1 for Growth--
Strain
CH1305 was transformed with pJZ203 (Table I) and used as the parent
strain for the mutant hunt. These transformants were grown to
mid-exponential phase (2 × 107 cells/ml) in
leucine-deficient medium. Cell suspensions were diluted in water and
plated on YEP-glucose plates at approximately 2,000 cells per plate.
These cells were mutagenized with UV irradiation to approximately 10%
survival and then incubated at 30 oC for 5-7 days to
allow the development of red color (see "Results"). As expected,
most colonies were white or sectored. Of 2 × 105
colonies screened, 330 solid red colonies were identified. Each individual red colony was streaked for single colonies on YEP-glucose to ensure that it was uniformly non-sectoring. The 330 non-sectoring strains were further transformed with pJZ205, a pRS316 plasmid that
expresses I-1 but lacks ADE3 (Table I). Transformants were selected on uracil-deficient, low adenine medium. We identified four
mutants (JC1007-78,-97,-319, and -323) that formed sectoring pJZ205
transformant colonies.
Isolation of Genes That Complement or Suppress I-1
Dependence--
Plasmid pJZ501 was isolated from a YCp50 wild-type
yeast library (33). It complemented the I-1-dependent
mutation in strain JC1007-97 based on the colony-sectoring trait. It
was isolated twice from approximately 40,000 Ura+
transformants. Additionally, YEp13 and YEp24 yeast genomic libraries (34, 35) were used to transform JC1007-97 strain to isolate high copy
gfa1-97 suppressors.
Construction of Gene Disruptions--
A DNA fragment containing
gfa1::URA3 was generated by a polymerase chain
reaction using oligonucleotide primers GFA1a (5'-AGG AAT AAC TGT ATT
TCT TTT CTT ATA TAG TTA TCA GGG CCT GTG CGG TAT TTC ACA CCG) and GFA1b
(5'-ATG GAA GTT CAA AAA TTA AAA GCG AAG GAG AAG TGA TTG TAG ATT GTA CTG
AGA GTG CAC) and pRS316 template DNA. Each primer contains 20 3' bases
that flank the pRS316 URA3 gene. The 40 5' bases of these
primers have sequences proximal to the start and end of the
GFA1 open reading frame. The polymerase chain reaction
fragment was transformed into JC746-9D by selecting transformants on
uracil-deficient medium supplemented with 2 mg of
D-glucosamine/ml. Desired transformants were recognized by their glucosamine auxotrophy and confirmed by Southern analysis. The
hxk2::URA3 mutation in p2341 was constructed by
insertion of a 1-kilobase pair URA3 HindIII fragment into a
HindIII site within HXK2 in a subclone of pBW112
(36). Correct integration of hxk2::URA3 in yeast
transformants was confirmed by polymerase chain reaction analysis of
yeast genomic DNA. Disruptions reg1::LEU2, reg2::URA3, and mig1::URA3
were introduced into yeast by transformation with fragments from
pBM1966, BS-reg2::URA3, or pJN41, respectively, as
described (37-39).
Protein and Glycogen Assays--
Protein concentrations were
determined by dye binding using a bovine serum albumin standard
(Bio-Rad). Iodine staining was used for qualitative assessment of
glycogen levels (5, 40). Dry weights and glycogen were assayed from
three cultures derived from independent transformants as described
(40).
Enzyme Assays--
To assay glutamine-fructose-6-phosphate
transaminase, cell extracts in 60 mM
KH2PO4, pH 7.0, 1 mM EDTA, 1 mM dithiothreitol were prepared by vortexing with glass
beads at 4 oC. The assay mixture contained 15 mM D-fructose 6-phosphate (Sigma) and 15 mM L-glutamine (Sigma) in extract buffer with
1-2.5 mg/ml protein extract. Incubation was started by addition of
extract and terminated after 1 h at 37 oC by heating
at 100 oC for 2 min. To measure the background of
D-glucosamine 6-phosphate and other interfering material,
the reaction was stopped immediately after adding the extract. After
cooling and centrifugation, D-glucosamine 6-phosphate was
determined in the supernatant by a modified Morgan-Elson procedure (41)
using a D-glucosamine standard. D-Glucosamine 6-phosphate yields 85% of the absorbance obtained with
D-glucosamine (41), and this correction factor has been applied.
To assay Glc7p protein phosphatase activity, yeast cell extracts were
made in 50 mM imidazole, pH 7.5, at 4 oC and
used immediately. Phosphorylase phosphatase activity was assayed using
32P-phosphorylase in the presence of 3 nM
okadaic acid as described (27, 28).
Permeabilized cells were used to assay
-galactosidase as described
(42). All enzyme assays were done on cultures derived from three or
more independent transformants. Two-tailed t tests were
performed on data to determine statistical significance.
Western Immunoblotting--
Cells were grown in synthetic media
with or without glucosamine. To determine the effect of growth phase on
the level of Glc7p, samples from middle logarithmic to stationary phase
were harvested, and crude protein extracts were prepared by vortexing
with glass beads. Typically, 50 µg protein per lane was loaded and
separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (10% w/v acrylamide). The resolved proteins were
transferred to nitrocellulose membranes and blocked with 5% dehydrated
skim milk in phosphate-buffered saline (8 mg of NaCl, 0.2 mg of KCl,
1.44 mg of Na2HPO4, and 0.24 mg of
KH2PO4 per ml, pH 7.4). Overnight incubation at
4 oC with anti-HA (1 µg/ml; 12CA5 Roche Molecular
Biochemicals), anti-yeast phosphoglycerate kinase (0.5 µg/ml, PGK,
Molecular Probes), or anti-I-1 (22) primary antibodies was followed by anti-mouse IgG-conjugated peroxidase (Cappel) secondary antibodies. Bands were finally visualized using luminol chemiluminescence reagents
(Pierce) and several exposures to XAR5 (Eastman Kodak Co.) film.
Northern Analysis--
Total yeast RNA was isolated,
fractionated on formaldehyde-agarose gels, and hybridized with
32P-labeled probes as described (31). The GLC7
probe was the 486-base pair EcoRI-SalI fragment
from pKC886. The ACT1 probe was from the plasmid pYact1
(43).
 |
RESULTS |
I-1 Inhibits a Subset of Glc7p Holoenzymes in Vivo--
Human I-1
was expressed in yeast using the strong, constitutive GPD1
promoter in various low and high copy vectors. I-1 inhibits yeast PP1
in vivo (28). Surprisingly, we failed to find any growth
impairments, which would be expected if I-1 expression severely
inhibited Glc7p activity. Anti-I-1 immunoblot analysis of I-1 yeast
transformant proteins confirmed expression of the human I-1 protein
(data not shown). Therefore, we compared the traits of strains
transformed with I-1 expressing and control plasmids to learn whether
any Glc7p holoenzymes were modulated by I-1 in vivo.
The Gac1p/Glc7p holoenzyme promotes glycogen synthesis in yeast (12).
Null mutations in GAC1 or missense mutations in
GLC7 greatly reduce glycogen accumulation (5, 44-46).
Therefore, glycogen accumulation provides an assay of the Gac1p/Glc7p
holoenzyme in vivo activity. Yeast transformed with plasmids
that express I-1 accumulated 20-26% less glycogen than control
transformants (Fig. 1A).
However, this reduction was small compared with the greater than 95%
reduction caused by some glc7 or gac1 mutations (12, 46) and was not statistically significant (p
0.18). These data indicate that the Gac1p/Glc7p holoenzyme activity is not
significantly inhibited by I-1 in vivo.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 1.
I-1 expression inhibits some Glc7p
holoenzymes in vivo. A, CH1305
transformants were grown for 48 h in uracil-deficient minimal
medium. Glycogen was quantitated as described (40). A two-tailed
t test showed that pJZ205 and pJZ206 transformant glycogen
levels differed insignificantly from pRS426 control transformants
(p = 0.3 and 0.18, respectively). B, three
independent JC746 transformants were sporulated for 3 days at 30° C
on SPOR plates. For each of the three sporulated patches, at least 200 cells were counted, and sporulation frequency was calculated from the
numbers of asci. C, the ipl1-1 strains JC1085-18B
(top and left) and JC1117-7D (bottom
and right) transformed with pJZ204 (2-µm TRP1
I-1) or its parent vector, pG-3 (2-µm TRP1), were
streaked on tryptophan-deficient minimal medium and incubated at the
indicated temperatures for 3 days.
|
|
Glc7p regulates two essential functions in the mitotic cell cycle as
follows: the G1- to S-phase transition and chromosome segregation (7, 24, 26). The former function is poorly understood and
has only been observed in pedigree analysis experiments (24). However,
chromosome segregation appears to require Glc7p activity to
dephosphorylate the kinetochore protein Ndc10p (47). Ndc10p
phosphorylation by protein kinase, Ipl1p, inhibits mitotic spindle
attachment (48). Temperature-sensitive lethal mutations in
ipl1 cause a ploidy increase that can be suppressed by
inhibition of Glc7p activity (6). We found that I-1 expression
suppressed the temperature-sensitive trait of ipl1-1 (Fig.
1C). The Sds22p/Glc7p is most likely the holoenzyme that
modulates chromosome segregation because sds22 mutants
arrest in the cell cycle in preanaphase (13, 14). Therefore, the
ipl1-1 suppression by I-1 suggests that the Sds22p/Glc7p
holoenzyme is inhibited by I-1 in vivo.
Glc7p holoenzymes participate in at least three distinct steps during
sporulation (46). The first two steps exploit unknown Glc7p
holoenzymes. First, Glc7p promotes transcription of IME1, encoding the main transcriptional inducer of early meiotic genes. Next,
an undefined step after IME1 expression, but before
premeiotic S-phase, requires Glc7p activity
(46).2 Finally, packaging of
meiotic spores appears to require the Gip1p/Glc7p holoenzyme (11, 46).
Diploid JC746 transformed with I-1-expressing or control plasmids was
transferred to solid sporulation medium, and the frequency of
sporulated cells was counted after 3 days. Remarkably, I-1 expression
failed to alter significantly the sporulation frequency (Fig.
1B). High copy plasmids that express truncated GLC7 genes behave like dominant-negatives because they can
suppress ipl1 and gcn2 protein kinase mutations
(6, 9). However, as far as the sporulation functions of Glc7p are
concerned, high copy truncated GLC7 had no detectable effect
(Fig. 1B). Additionally, sporulation frequency was
unaffected by high copy GLC8. Sporulation of yeast diploids
normally yields four haploid spores within a tetrad. We previously
found that some glc7 alleles yielded a high frequency of
dyads (46). Dyads are produced instead of tetrads when one meiotic
division fails to occur or spore packaging is incomplete. None of the
transformants in Fig. 1B produced more than 2% dyads.
Together these data show that neither truncated GLC7, I-1,
nor high copy GLC8 inhibit Glc7p sporulation functions.
Some GFA1 Mutants Require I-1 Expression to Grow--
Glc7p
activity must be tightly controlled because it is essential for growth
yet can inhibit growth if overexpressed (6, 24, 26, 49). Since the
results of the previous section showed that I-1 inhibits a subset of
Glc7p holoenzymes, we took advantage of ectopic I-1 expression to
isolate mutants that require I-1 expression for viability. Such mutants
would illustrate novel aspects of Glc7p function. We exploited a
synthetic lethal screen in which mutants that require I-1 expression to
grow exhibit a solid red colony color, whereas wild-type cells yield
colonies with red and white sectors (see "Experimental
Procedures"). This scheme identified four mutants that were dependent
on I-1 for viability. Diploids heterozygous for these mutations did not
require I-1 to grow. Therefore, each I-1-dependent mutation
was recessive. Additionally, tetrad analysis of diploids that were
heterozygous for these mutations displayed 2:2 segregation for growth
rate, which indicates that the mutants harbor single, nuclear mutations that confer I-1 dependence for growth. Moreover, complementation analysis indicated three complementation groups. The remainder of this
paper concerns the characterization of the two allelic mutations in
strains JC1007-97 and JC1007-319. Because traits of the JC1007-97
strain were easier to score, our further analyses used JC1007-97 exclusively.
The I-1-dependent mutation in JC1007-97 is allelic to
GFA1. We isolated plasmids from a wild-type YCp50 library
that complement the I-1-dependent mutation in
JC1007-97/pJZ203. Transformants with complementing plasmids were
recognized by their sectoring trait. Two independent plasmids that
complement the JC1007-97 I-1-dependent mutation contained
overlapping DNA from chromosome VII. Further analysis localized the
complementing gene to GFA1, which encodes
glutamine-fructose-6-phosphate transaminase (EC 2.6.1.16) (50). A
wild-type URA3 gene was integrated at the GFA1
locus in JC1053-3D by integrative transformation using plasmid p2368.
When this transformant was crossed to JC1007-97/pJZ203, tetrad analysis
of the sporulated diploid revealed no recombination between the
integrated URA3 and the I-1-dependent mutation.
Therefore, by these complementation and linkage criteria, the
I-1-dependent mutations in JC1007-97 and JC1007-319 are
alleles of GFA1 and will be called gfa1-97 and
gfa1-319, respectively.
The Gfa1-97 Mutation Reduces but Does Not Eliminate
Glutamine-Fructose-6-phosphate Transaminase
Activity--
Glutamine-fructose-6-phosphate transaminase catalyzes
the formation of glucosamine 6-phosphate, which is the first and
rate-limiting step for protein glycosylation and chitin synthesis (51).
We confirmed that disruption of the GFA1 gene generates a
strain that is auxotrophic for glucosamine (50) by construction of a
gfa1::URA3 mutant. We assayed the
glutamine-fructose-6-phosphate transaminase enzyme activity of crude
extracts from wild-type, gfa1-97, and
gfa1::URA3 mutant strains. As shown in Table
II, the gfa1-97 mutant had
approximately 35% of the wild-type specific activity, whereas activity
in a gfa1::URA3 null mutant was undetectable. Despite the reduction in enzyme activity in gfa1-97
(JC1007-97) cells, when transformed with an I-1-expressing plasmid
(JC1007-97/pJZ203), they grew at the same rate as wild-type on
glucosamine-free minimal medium. This paradox was resolved by
experimental results described later. Additionally, the GFA1
genotype significantly influenced the intracellular glucosamine (Table
II); however, the mechanism is unknown.
View this table:
[in this window]
[in a new window]
|
Table II
Glutamine-fructose-6-phosphate transaminase activity and intracellular
glucosamine in wild-type and gfa1 mutant strains
|
|
Since glucosamine synthesis in the gfa1-97 mutant was
reduced, we tested if extracellular glucosamine could suppress the
I-1-dependent trait of gfa1-97. To test this
possibility, JC1007-97/pJZ203 cells were streaked on plates that
contained 5 mg of glucosamine/ml. On this medium, JC1007-97/pJZ203
mutant cells readily lost the plasmid pJZ203 and became white or
sectored (Fig. 2A). Such
gfa1-97 cells without a source of I-1 were dependent on
glucosamine to grow. This result indicates that the reduced glucosamine
synthesis in JC1007-97 is responsible for its I-1 dependence, and
extracellular glucosamine could suppress the I-1 dependence of the
gfa1-97 mutation.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 2.
Suppression of gfa1-97
traits by growth media. A, JC1007-97 was streaked
on low adenine synthetic complete medium with the indicated carbon
sources, glucosamine (5 mg/ml), or sorbitol (0.8 M). Plates
were incubated at 30° C 4 days before photography. Great retention
of pJZ203 produces solid red colonies, which are
dark in this figure. In contrast, white colonies or sectors
derive from cells that lost pJZ203. B, glucosamine or
sorbitol suppressed the gfa1-97 temperature sensitivity.
Ten-fold serial dilutions of CH1305 (GFA1) and JC1007-97
(gfa1-97) were spotted on YEP-glucose, YEP-glucose with 5 mg
glucosamine/ml, YEP-glucose with 0.8 M sorbitol,
YEP-galactose, or YEP-fructose. Plates were incubated at 37° C for 4 days before photography.
|
|
Because gfa1::URA3 null mutants had an
undetectable glutamine-fructose-6-phosphate transaminase activity, we
reasoned that they might also be I-1-dependent. However,
since gfa1::URA3 strain can only grow in the
presence of glucosamine, the I-1 dependence could not be tested.
Expressing I-1 in gfa1::URA3 mutant cells did not
relieve the glucosamine requirement for growth.
Phenotypic Characterization of Gfa1-97--
Suppression of the
I-1 dependence by growth in medium containing 5 mg of glucosamine/ml
provided an easy way to obtain JC1007-97 plasmid-free cells to study
traits of gfa1-97 without I-1 present. These plasmid-free
JC1007-97 cells produced completely white colonies of Leu
cells. To distinguish the plasmid-bearing and plasmid-free cells, they
will be labeled explicitly as "JC1007-97/pJZ203" and
"JC1007-97," respectively.
The gfa1-97 mutation caused temperature-sensitive growth on
media without glucosamine. JC1007-97 cells grew as well as wild-type CH1305 cells at temperatures up to 25 oC. However, at
30 oC and higher temperatures, only 0.1% of the cells
formed visible colonies after 2 days, the majority of cells either died
at the single-cell stage or divided several times to form microcolonies (Fig. 3A). No specific cell
cycle arrest was observed for these cells. Cells stopped growing and
produced buds of differing sizes. At 37 oC, the growth
defect trait was exacerbated; no colonies appeared after 5 days of
incubation. The majority of cells did not divide and a large population
lysed or had long, slender buds when examined microscopically (Fig.
3B).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 3.
Demonstration of gfa1-97
traits without I-1. A, temperature sensitivity
caused by gfa1-97 was apparent from growth of CH1305
(GFA1) and JC1007-97 (gfa1-97) transformants at
different temperatures. The genotypes of strains and plasmids are shown
in the legend. Plasmids in JC1007-97 transformants are (starting at
top, going clockwise) as follows: pJZ504, pJZ208,
p2168, pJZ206, pJZ205, and pRS426, respectively. Transformants were
streaked on YEP-glucose plates and incubated for three days at the
indicated temperatures. B, the gfa1-97 mutation
caused arrest at all points in the cell cycle on glucosamine-free
medium. CH1305 or JC1007-97 cells grown at 37° C for 24 h in
YEP-glucose were fixed and photomicrographed. C, the
gfa1-97 cells exhibited a pre-exponential phase growth lag,
retarded exponential growth rate, and reduced growth yield compared
with wild-type cells in liquid cultures. Growth of liquid
30° C YEP-glucose (without added glucosamine) cultures
of CH1305 (triangles, dashed lines) and JC1007-97
(circles, solid lines) were monitored by 600 nm light
scattering. Cell counts by hemocytometer showed similar results.
|
|
Growth of JC1007-97 in liquid cultures showed three impairments
compared with wild-type cells (Fig. 3C). First, the
JC1007-97 mutant cells were significantly delayed at entering the
exponential growth phase. Second, JC1007-97 cells divided at 80% the
growth rate of wild-type cells during exponential phase. Third, the
maximum cell density of the JC1007-97 mutant cells was 70% of the
wild-type. Note that the rich YEP-glucose medium used for liquid
culture growth initially contains some glucosamine from the yeast
extract ingredient. Growth on fructose was similar to that observed on glucose. However, growth on galactose was unimpaired. In fact, galactose suppressed the I-1 dependence trait of gfa1-97 and
partially suppressed the temperature-sensitive trait (Fig. 2).
Glucosamine is important for chitin synthesis and protein
glycosylation, which are required for cell wall integrity (51). Mutants
with defects in cell wall integrity lyse at restrictive temperatures
but can be rescued in media with greater osmolarity. Therefore, we
tested if the addition of sorbitol or NaCl to the medium could rescue
the growth defect of the JC1007-97 strain. JC1007-97 grew well at
30 oC in glucosamine-free media supplemented with 0.8 M sorbitol or 0.25 M NaCl (data not shown).
Sorbitol suppressed the I-1 dependence and temperature-sensitivity
traits of gfa1-97 (Fig. 2). NaCl suppressed these traits
identically to sorbitol (data not shown). This suppression was
consistent with gfa1-97 causing a defect in cell wall integrity.
Inhibition of Glc7p Activity Suppresses Traits of Gfa1-97--
In
addition to the known function of I-1 to inhibit PP1 activity, it is
possible that gfa1-97 results in a reliance on a different I-1 function. Therefore, we tested whether inhibition of Glc7p by some
other means could suppress gfa1-97. High copy, truncated GLC7 genes (GLC7
) behave as dominant-negatives
(6, 9). Mutations in gcn2 and ipl1 protein kinase
genes are suppressed by GLC7
because these protein
kinases phosphorylate known or suspected Glc7p substrates. Therefore,
we tested whether the inhibition of Glc7p activity via
GLC7
could substitute for I-1. When JC1007-97 was
transformed with p2168, which carries GLC7
at high copy, the I-1 dependence was relieved (Fig. 4).
Additionally, the slow growth of JC1007-97 at 30 oC was
suppressed by GLC7
(Fig. 3A).

View larger version (85K):
[in this window]
[in a new window]
|
Fig. 4.
Suppression of JC1007-97 I-1 dependence
trait. JC1007-97 transformed with various URA3 plasmids
was grown for 6 days on low adenine uracil-deficient medium before
photography. White or sectored colonies indicate loss of pJZ203 and
suppression of the I-1 dependence trait. The smaller, white colonies
visible in the panels are respiratory-deficient clones, which do not
turn red, despite the retention of pJZ203. The panels are labeled with
the plasmid genotypes. The plasmids used were pRS316, p2168, pJZ205,
pJZ208, pJZ206, and pJZ209.
|
|
I-1 inhibits PP1 activity only when threonine 35 of I-1 is
phosphorylated (20, 22). A mutant form of I-1 in which alanine is
substituted for threonine 35 cannot inhibit PP1 activity in vitro because it cannot be phosphorylated (20, 22). Wild-type I-1
interacts with Glc7p in the two-hybrid assay, whereas the I-1-T35A
mutant does not (29). In addition, I-1 suppresses the ipl1
temperature-sensitive trait, whereas I-1-T35A does not (Fig. 1 and data
not shown). We tested whether I-1-T35A could suppress traits of
gfa1-97. We found that expression of I-1-T35A could neither
suppress the I-1 dependence of gfa1-97 as scored by the colony sectoring trait (Fig. 4) nor the temperature-sensitive growth at
30 and 37 oC on glucosamine-free media (Fig.
3A). Taken together, these genetic data show that
gfa1-97 was isolated as a I-1-dependent mutation because Glc7p inhibition was required for glucosamine-free growth.
Glucosamine Does Not Alter Glc7p Activity or Protein
Levels--
Why do gfa1-97 cells require Glc7p inhibition
for growth? The first possibility we considered was that reduced
glucosamine biosynthesis in some way increased Glc7p activity, which is
toxic (24, 26, 27). This explanation would predict that extracellular glucosamine reduces Glc7p activity because glucosamine relieves the
I-1-dependent trait of gfa1-97. Since glycogen
synthase is a Glc7p substrate and its activity is dependent on
phosphorylation (5), we analyzed glycogen accumulation in wild-type and
gfa1-97 mutant cells. A slightly darker iodine staining was
observed with gfa1-97 cells, indicating an increase in
glycogen accumulation and thus potentially elevated Glc7p activity.
Quantitative glycogen assays confirmed that gfa1-97 cells
accumulated 20% more glycogen than wild type (data not shown).
Although increased glycogen accumulation can be caused by increases in
Glc7p activity, many other factors can influence glycogen levels (5).
Glc7p activity was specifically assayed in yeast crude extracts by
[32P]phosphorylase dephosphorylation in the presence of
okadaic acid (11, 27, 28). By this assay we did not find significant differences of Glc7p-specific activity between isogenic
gfa1-97, gfa1::URA3, and wild-type
cells (data not shown). Therefore, despite increases of glycogen that
might be caused by increases of Glc7p activity, we were unable to
document a significant change in Glc7p-specific activity by in
vitro assays.
We also examined Glc7p protein levels using immunoblot analysis. Glc7p
protein levels were monitored using an HA-GLC7 fusion gene
on a centromeric plasmid. This gene complements all GLC7 traits and allowed the relative Glc7p protein levels to be assayed using anti-HA antibody. No consistent differences of Glc7p levels were
found between wild-type and gfa1-97 cells. Furthermore,
extracellular glucosamine had no effect on the levels of Glc7p in
wild-type or gfa1-97 cells (data not shown). Moreover, we
found only minor differences of GLC7 mRNA levels in
wild-type and gfa1-97 cells harvested at equivalent time
points (data not shown). The GLC7 mRNA abundance
increased in latter growth phase samples for both cultures. This
induction in late exponential phase has been noted before (4). These
experimental results demonstrate that gfa1-97 cells do not
have increased Glc7p activity or protein levels.
High Copy Suppressors of Gfa1-97--
To help elucidate the
reason gfa1-97 cells require Glc7p inhibition for growth, we
sought high copy suppressors of gfa1-97. High copy libraries
were screened for plasmids that suppressed the I-1 dependence of
JC1007-97/pJZ203 by the colony-sectoring assay. Because Glc7p
inhibition would increase the phosphorylation of Glc7p substrates,
potential high copy suppressors were expected to be protein kinase
genes. Therefore, 24 protein kinase genes in 2-µm vectors were also
specifically tested. By these routes, we found that RHO1, PKC1,
BCK1, MKK1, MKK2, MPK1, SNF1, and PBS2 could suppress
gfa1-97. Except for PBS2 and SNF1,
these genes encode components of the Rho1/Pkc1 MAP kinase pathway
(52-55). This pathway maintains cell wall integrity (56). Except for RHO1, all these suppressing genes encode protein kinases.
Glucosamine is used in the synthesis of glycoproteins and chitin, which
are both components of the cell wall. The isolation of these high copy
suppressors suggests that the stress in cell wall biosynthesis caused
by gfa1-97 can be relieved by hyperactivity of the Rho1/Pkc1 pathway. Moreover, these suppression results implicate Glc7p in antagonizing the activity of this pathway.
The PPZ protein phosphatases encoded by PPZ1 and
PPZ2 antagonize some aspects of the Rho1/Pkc1 pathway.
Because the catalytic domains of PPZ proteins are very homologous to
PP1 enzymes, we considered I-1 might inhibit activity of these PP1
homologues. Therefore, we tested whether I-1 expression recapitulated
the increased salt or caffeine resistance traits of ppz1
(57). We found that wild-type yeast transformed with plasmids that
express I-1 or I-1-T35A were equally sensitive to caffeine and lithium (data not shown). Therefore, we have no evidence that I-1 inhibits Ppz1p or Ppz2p in vivo.
Glc7p and the Pkc1p Pathway Regulate GFA1 Transcription--
The
pheromone-responsive transcription factor Ste12p and its coactivator
Mcm1p have binding sites in the GFA1 promoter. Both Ste12p
and Mcm1p are multiply phosphorylated proteins (58, 59). Because the
transcriptional activity of Ste12p and Mcm1p is regulated by their
phosphorylation, we explored whether GFA1 transcription was
altered in strains with inhibited Glc7p activity. The E. coli lacZ gene was fused to GFA1 at codon 73 and integrated
at the GFA1 locus so that GFA1 transcription
could be quantitated by
-galactosidase assays (see "Experimental
Procedures"). Consistent with pheromone induction of GFA1
mRNA (50),
-galactosidase activity from GFA1-lacZ was
induced ~3-fold by pheromone (Fig. 5A). High copy I-1 and
GLC7
increased GFA1-lacZ
-galactosidase activity 29 and 67%, respectively (Fig. 5B). Although these
increases of GFA1 transcription were small, both were
significant (p < 0.005 and p < 0.0005, respectively). Enzyme assays showed that I-1 increased glutamine-fructose-6-phosphate transaminase activity from
gfa1-97 but not wild-type cells (data not shown). Moreover,
elimination of the Glc7p/Reg1p holoenzyme by
reg1::LEU2 increased GFA1-lacZ
-galactosidase activity 78% (Fig. 5B). These data reveal
that Glc7p activity inhibits GFA1 transcription and that
increased GFA1 transcription can overcome the
gfa1-97 glucosamine auxotrophy.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Attenuation of Glc7p activity increases
GFA1 and HXT4 transcription.
A, CH1305/p2368 (GFA1-lacZ) cells were grown to
mid-exponential phase (A600 = 0.7-1.0) in
YEP-glucose. The culture was split, and 10 µg of -factor per ml
was added to one culture (triangles) at time 0, and cell
samples were assayed for -galactosidase. The control culture
(circles) had no -factor added. B, the
GFA1-lacZ -galactosidase activity was assayed for
exponential phase cultures. The left three data are from
CH1305/p2368 cells transformed with pTVS30, pJZ203, or p2155 grown in
leucine-deficient medium. The center two bars show data from
CH1305/p2368 or CH1305 reg1::LEU2/p2368 cells
grown in YEP-glucose. The right three data are from
CH1305/p2397 cells transformed with YEp352, YEp352-PKC1, or
YEp352-MPK1 grown in uracil-deficient medium. C,
CH1305/pBM2800 transformed with pTSV30, pJZ203, or p2155 were grown in
leucine-, uracil-deficient medium and assayed for HXT4-lacZ
-galactosidase activity. B and C, the relevant
genotype of the plasmids is shown within the bar. Assays
were performed on three or more cultures derived from independent
transformants.
|
|
To learn if the high copy suppressors we isolated also suppress
gfa1-97 by means of increasing GFA1
transcription, GFA1-lacZ
-galactosidase activity was
assayed for cells transformed with suppressor gene plasmids. These
assays revealed that all high copy suppressor genes increased
GFA1 transcription to various degrees (Fig. 5B
and data not shown). Induction of GFA1-lacZ by MPK1/SLT2, the MAP kinase of the cell wall integrity
pathway, reveals that suppression by RHO1, PKC1,
BCK1, MKK1, and MKK2 can be explained by their
stimulation of Mpk1p.
Snf1p and Reg1p regulate the transcription of glucose-repressed genes
(60). Our results showed that overexpression of SNF1 suppressed gfa1-97 by increasing GFA1
transcription. Inactivation of REG1 also increased
GFA1-lacZ expression (Fig. 5B). Therefore, we
were interested in whether inhibition of Glc7p by I-1 or
GLC7
could increase transcription of other genes, such as
HXT4, regulated by Snf1p and Reg1p (37). We found that
either I-1 or GLC7
induced HXT4-lacZ
expression (Fig. 5C). Regulation of HXT4 also
uses signals derived from HXK2-encoded hexokinase, and
dephosphorylated Mig1p represses HXT4 (37). Gene disruptions
of HXK2, MIG1, REG1, or REG2 were made in a diploid heterozygous for
gfa1-97. These strains were sporulated, tetrads dissected,
and spores analyzed to explore whether null mutations in these genes
could suppress traits of gfa1-97. The
reg1::LEU2 gfa1-97 double mutant spores grew
poorly on all media, so potential gfa1-97 suppression by
reg1 could not be scored. However, all of the other null
mutations yielded two slow growing gfa1-97 spores per
tetrad, showing that they could not suppress the gfa1-97
slow growth trait.
 |
DISCUSSION |
PP1 holoenzymes achieve diversity by the variety of noncatalytic
subunits that can associate with catalytic subunits. The single PP1
catalytic subunit, encoded by GLC7 in S. cerevisiae, is known to regulate a variety of physiological
processes. Glc7p binds to at least nine different noncatalytic subunits
(10). Mammalian PP1 enzymes are also regulated by inhibitor proteins. Inhibitor I-1 was known to inhibit Glc7p activity in vitro
(28). In this work we show I-1 also inhibits Glc7p in vivo,
although not all holoenzymes appear sensitive to I-1.
Separate domains of I-1 participate in PP1 binding and inhibition (61,
62). The amino acid sequence KIQF in I-1 is similar to a sequence found
in many PP1 noncatalytic subunits, and it is required for I-1
inhibition function (23, 61, 63). This sequence is thought to be an
interface for PP1 binding. Because Reg1p and Gac1p noncatalytic
subunits contain a sequence similar to KIQF (63), I-1 is unlikely to
bind and inhibit Glc7p while Glc7p is bound to either Reg1p or Gac1p.
However, depending on relative affinities and protein levels, I-1 could
potentially displace Reg1p or Gac1p from Glc7p, thereby reducing the
catalytic activity of those holoenzymes. Our data are consistent with
in vivo inhibition of the Reg1p/Glc7p holoenzyme by I-1
because expression of I-1 in yeast mimics the reg1 induction
of GFA1 and HXT4 transcription (Fig. 5, and see
Ref. 37). In contrast, Gac1p/Glc7p holoenzyme inhibition by I-1 is, at
best, minor (Fig. 1). Because Sds22p lacks a KIQF-homologous domain
(63), the Sds22p/Glc7p holoenzyme could potentially bind I-1 without
dissociation. Regardless of the mechanism, I-1 suppression of
ipl1 temperature sensitivity argues that I-1 inhibits the
Sds22p/Glc7p holoenzyme in vivo (Fig. 1).
I-1 residues around Thr-35 are thought to occupy the PP1-active site
and competitively inhibit PP1 substrate access (64). PP1 inhibition by
I-1 requires I-1 Thr-35 phosphorylation (20). In mammalian cells
cAMP-dependent protein kinase phosphorylates I-1 in
response to extracellular hormones (1-3). However, yeast cAMP-dependent protein kinase is responsive to nutritional
signals via the RAS GTPase (5, 65). Nitrogen starvation and the absence of glucose promote sporulation of diploid yeast cells. These conditions apparently reduce cAMP-dependent protein kinase activity
because hyperactive cAMP-dependent protein kinase inhibits
sporulation (66). We have previously found that Glc7p activity is
required for at least three points in the meiotic sporulation program
(46). In this work we failed to detect I-1 inhibition of Glc7p during sporulation (Fig. 1). Although this could be a consequence of I-1
hypophosphorylation, the observation that high copy GLC7
or GLC8 transformants also sporulated normally indicates
that the unknown Glc7p holoenzymes that control meiosis and sporulation are not subject to the same inhibitors as other holoenzymes.
We hypothesize that Glc7p is naturally subject to inhibition. Three
observations prompt this hypothesis. First, intermediate Glc7p activity
is required for normal cellular growth since substantial increases or
decreases of the wild-type activity kills yeast cells. Second, several
PP1 inhibitors exist in mammalian cells, and if they were
evolutionarily ancient would also be found in the unicellular eukaryote, S. cerevisiae. However, only the I-2 homologue
Glc8p has been found in yeast, and it appears to predominantly activate Glc7p activity (24, 25). Our data demonstrate no Glc8p influence on
Glc7p holoenzymes that regulate sporulation or GFA1
transcription, respectively. Finally, assays of yeast PP1 activity are
exquisitely sensitive to crude extract
dilution.3 This behavior is
similar to mammalian PP1 assays (1-3) and is evidence of PP1
inhibitors present in the crude extract. The prospect of natural Glc7p
inhibitors spurred our hunt for mutants that depend on I-1 expression
for viability.
Two independent mutants, which required I-1 expression for viability,
were isolated and discovered to contain mutations in GFA1,
which encodes glutamine-fructose-6-phosphate transaminase, the
glucosamine biosynthetic enzyme. These mutants could not grow without
glucosamine if I-1-T35A, which cannot inhibit PP1, was expressed.
Moreover, inhibition of in vivo Glc7p activity by
GLC7
revealed that the gfa1 mutants need Glc7p
inhibition to grow without glucosamine. Neither gfa1-97 nor
extracellular glucosamine influenced Glc7p activity, Glc7p protein, or
GLC7 RNA levels (data not shown). Therefore,
gfa1-97 mutant cells have a condition where normal Glc7p
activity forbids glucosamine-free growth. We considered that Glc7p
regulated glutamine-fructose-6-phosphate transaminase by
dephosphorylation because this enzyme from other fungal species is
regulated by phosphorylation (51, 67). However, changes in Glc7p
activity did not significantly affect enzyme activity in wild-type
cells (data not shown). We demonstrated that Glc7p inhibition induces
GFA1 transcription (Fig. 5) and that increased GFA1 transcription restores gfa1-97
glutamine-fructose-6-phosphate transaminase to wild-type levels (data
not shown). Therefore, gfa1 mutants were isolated as
I-1-dependent mutants because they required GFA1
transcription induction that results from Glc7p inhibition.
The mating pheromone response pathway induces GFA1
transcription (50). Pheromone exposure induces haploid cells to
initiate polarized cell growth toward the pheromone source. Since
glucosamine and its products are required for cell wall growth,
GFA1 induction under these conditions is understandable.
Ste12p and Mcm1p activate transcription of genes in response to
pheromones in both haploid cell types (68), and DNA 5' to
GFA1 contains binding sites for these two proteins (50, 59).
However, glucosamine biosynthesis is needed at all stages of growth,
not merely in response to pheromones. In fact, Mcm1p coactivates
transcription of many genes essential for cell cycle progression, cell
wall, or cell membrane biosynthesis, and it may participate in the
M/G1 expression of GFA1 (59, 69-71).
We showed that high copy RHO1, PKC1, and other
protein kinase genes in the Pkc1p MAP kinase cascade could suppress the
glucosamine auxotrophy of gfa1-97. This cascade activates
cell wall biosynthetic genes during periods of polarized cell growth
(56, 72). The Pkc1p MAP kinase cascade suppression of
gfa1-97 appears to be via induction of GFA1
transcription because even overexpressing Mpk1p, the terminal kinase in
the cascade could induce GFA1-lacZ (Fig. 5B).
Mpk1p phosphorylates the transcriptional factor, Rlm1p, which partially
mediates Mpk1p function (73). However, the region 5' to GFA1
lacks recognizable Rlm1p-binding sites. Therefore, the activation of
GFA1 may use an activation mechanism similar to
FKS2, which is also responsive to Mpk1p activation via a
cis-DNA region that lacks Rlm1p-binding sites (72).
Surprisingly, high copy PBS2 also suppressed
gfa1-97. Pbs2p is a protein kinase in the osmotic stress
responsive Hog MAP kinase cascade, which is distinct from the Pkc1p MAP
kinase cascade (56). PBS2 may suppress gfa1-97 by
its documented activation of Mcm1p (74, 75).
Glucosamine levels should be regulated in response to growth rate and
nutrient levels to ensure an appropriate supply of this sugar for cell
wall and glycoprotein biosynthesis. Evidence of a mechanism to modulate
intracellular glucosamine levels was revealed by the influence that
gfa1 genotype had on these levels (Table II). Since I-1 and
Glc7p activity regulate the glucose transporter encoded by
HXT4 (Fig. 5C), we hypothesize that they also
regulate glucosamine transporters in a manner that senses glucosamine
biosynthetic capacity. Growth on galactose allows derepression of
glucose-repressed genes and can suppress the I-1-dependent
trait of gfa1-97 (Fig. 2). Similarly, reg1
mutations or SNF1 overexpression also suppress gfa1-97 (this work) and derepress glucose-repressible genes
(60). Glucose repression of GFA1 could explain these
observations; however, this possibility has not been tested. If
GFA1 transcription were glucose-repressible, it would be
novel because mig1 mutations do not increase GFA1
transcription nor suppress gfa1-97 I-1 dependence. Mig1p is
responsible for glucose repression of other genes (60). Furthermore,
gfa1-97 and GFA1+ cells grown on rich
medium showed a greater difference in glutamine-fructose-6-phosphate transaminase activity than cells grown in minimal medium (data not
shown). This finding vividly demonstrates the influence that extracellular nutrient levels and growth rate have on Gfa1p regulation.
Glc7p regulates transcription of several genes in S. cerevisiae. Evidence has implicated the Glc7p/Reg1p holoenzyme in
regulating transcription of SUC2, INO1,
ADH2, HXT2, HXT4, and IME1
(8, 37, 46, 76-78) and Glc7p/Gac1p in regulating CUP1 (79).
In some cases a candidate Glc7p phosphoprotein substrate is genetically implicated, but none have been proven by rigorous biochemical analyses.
The results in this paper add GFA1 to the list of genes regulated by Glc7p/Reg1p. Similar to INO1 regulation,
GFA1 transcription was increased by elevated Snf1p activity
but not by mig1 or hxk2 mutations (76).
Curiously, only Mcm1p and Ste12p are known to regulate GFA1
transcription, and these regulators are distinct from the proteins
known to regulate INO1 (76, 77). Therefore, to explain the
role of Glc7p/Reg1p holoenzyme in transcriptional regulation requires
postulating that it dephosphorylates a number of different proteins or
that it dephosphorylates proteins that function at many promoters such
as TATA-binding proteins or components of RNA polymerase II holoenzyme.
One of the other I-1-dependent mutations we isolated was in
SPT6, which encodes a protein that influences chromatin
structure and RNA polymerase elongation (80, 81). Further work will be
required to define the Glc7p substrates responsible for these
transcriptional effects.
 |
ACKNOWLEDGEMENTS |
We thank Shirish Shenolikar, David Eide, and
Judy Wall for valuable discussions, suggestions, and comments on this
manuscript. We also thank Kim Arndt, George Boguslawski, Connie Holm,
David Levin, Glen Kawasaki, John Pringle, Shirish Shenolikar, and Keith Yamamoto for sharing reagents used in this study. We thank Jason Doke
for excellent technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grant GM40326 (to J. F. C.) and funds from the Molecular Microbiology and Immunology Department, University of Missouri.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This paper is dedicated to Jeanne Cannon, 1939-1999.
Supported in part by National Institutes of Health Training Grant AI07276.
§
To whom correspondence should be addressed: Dept. of Molecular
Microbiology and Immunology, M607 Medical Science Bldg., University of
Missouri, Columbia, MO 65212. Tel.: 573-882-2780; Fax: 573-882-4287; E-mail: CannonJ@missouri.edu.
Published, JBC Papers in Press, April 10, 2000, DOI 10.1074/jbc.M000918200
2
L. Li and J. F. Cannon, unpublished observations.
3
M. Khalil and J. F. Cannon, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
PP1, protein
phosphatase-1;
MAP, mitogen-activated protein;
I-1, Inhibitor-1;
HA, hemagglutinin.
 |
REFERENCES |
| 1.
|
Cohen, P
(1989)
Annu. Rev. Biochem.
58,
453-508
|
| 2.
|
Mumby, M. C.,
and Walter, G.
(1993)
Physiol. Rev.
73,
673-699
|
| 3.
|
Shenolikar, S.
(1994)
Annu. Rev. Cell Biol.
10,
55-86
|
| 4.
|
Feng, Z. H.,
Wilson, S. E.,
Peng, Z. Y.,
Schlender, K. K.,
Reimann, E. M.,
and Trumbly, R. J.
(1991)
J. Biol. Chem.
266,
23796-23801
|
| 5.
|
Cannon, J. F.,
Pringle, J. R.,
Fiechter, A.,
and Khalil, M.
(1994)
Genetics
136,
485-503
|
| 6.
|
Francisco, L.,
Wang, W.,
and Chan, C. M.
(1994)
Mol. Cell. Biol.
14,
4731-4740
|
| 7.
|
Hisamoto, N.,
Sugimoto, K.,
and Matsumoto, K.
(1994)
Mol. Cell. Biol.
14,
3158-3165
|
| 8.
|
Tu, J.,
and Carlson, M.
(1995)
EMBO J.
14,
5939-5946
|
| 9.
|
Wek, R. C.,
Cannon, J. F.,
Dever, T. E.,
and Hinnebusch, A. G.
(1992)
Mol. Cell. Biol.
12,
5700-5710
|
| 10.
|
Stark, M. J.
(1996)
Yeast
12,
1647-1675
|
| 11.
|
Tu, J.,
Song, W.,
and Carlson, M.
(1996)
Mol. Cell. Biol.
16,
4199-4206
|
| 12.
|
François, J. M.,
Thompson-Jaeger, S.,
Skroch, J.,
Zellenka, U.,
Spevak, W.,
and Tatchell, K.
(1992)
EMBO J.
11,
87-96
|
| 13.
|
Hisamoto, N.,
Frederick, D. L.,
Sugimoto, K.,
Tatchell, K.,
and Matsumoto, K.
(1995)
Mol. Cell. Biol.
15,
3767-3776
|
| 14.
|
MacKelvie, S. H.,
Andrews, P, D.,
and Stark, M. J.
(1995)
Mol. Cell. Biol.
15,
3777-3785
|
| 15.
|
Nimmo, G. A.,
and Cohen, P.
(1978)
Eur. J. Biochem.
87,
341-351
|
| 16.
|
Hemmings, H. C.,
Nairn, A. C.,
Elliott, J. I.,
and Greengard, P.
(1990)
J. Biol. Chem.
265,
20369-20376
|
| 17.
|
Park, I.-K.,
and DePaoli-Roach, A. A.
(1994)
J. Biol. Chem.
269,
28919-28928
|
| 18.
|
Beullens, M.,
Stalmans, W.,
and Bollen, M.
(1996)
Eur. J. Biochem.
239,
183-189
|
| 19.
|
Van Eynde, A.,
Wera, S.,
Beullens, M.,
Torrekens, S.,
Van Leuven, F.,
Stalmans, W.,
and Bollen, M.
(1995)
J. Biol. Chem.
270,
28068-28074
|
| 20.
|
Huang, F. L.,
and Glinsmann, W. H.
(1976)
Eur. J. Biochem.
70,
419-426
|
| 21.
|
Aitken, A.,
and Cohen, P.
(1982)
FEBS Lett.
147,
54-58
|
| 22.
|
Endo, S.,
Zhou, X.,
Connor, J.,
Wang, B.,
and Shenolikar, S.
(1996)
Biochemistry
35,
5220-5228
|
| 23.
|
Egloff, M. P.,
Johnson, D. F.,
Moorhead, G.,
Cohen, P. T.,
Cohen, P.,
and Barford, D.
(1997)
EMBO J.
16,
1876-1887
|
| 24.
|
Cannon, J. F.,
Clemens, K. E.,
Morcos, P. A.,
Nair, B. M.,
Pearson, J. L.,
and Khalil, M.
(1995)
Adv. Protein Phosphatases
9,
215-236
|
| 25.
|
Tung, H. Y.,
Wang, W.,
and Chan, C. S.
(1995)
Mol. Cell. Biol.
15,
6064-6074
|
| 26.
|
Black, S.,
Andrews, P. D.,
Sneddon, A. A.,
and Stark, M. J. R.
(1995)
Yeast
11,
747-759
|
| 27.
|
Zhang, S.,
Guha, S.,
and Volkert, F. C.
(1995)
Mol. Cell. Biol.
15,
2037-2050
|
| 28.
|
Cohen, P.,
Schelling, D. L.,
and Stark, M. J.
(1989)
FEBS Lett.
250,
601-606
|
| 29.
|
Connor, J. H.,
Quan, H. Q.,
Ramaswamy, N. T.,
Zhang, L.,
Barik, S.,
Zheng, J.,
Cannon, J. F.,
Lee, E. Y. C.,
and Shenolikar, S.
(1998)
J. Biol. Chem.
273,
27716-27724
|
| 30.
|
Kranz, J. E.,
and Holm, C.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6629-6633
|
| 31.
|
Sherman, F.,
Fink, G. R.,
and Hicks, J. B.
(1986)
Laboratory Course Manual for Methods in Yeast Genetics
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 32.
|
Schena, M.,
Picard, D.,
and Yamamoto, K. R.
(1991)
Methods Enzymol.
194,
389-398
|
| 33.
|
Rose, M. D.,
Novick, P.,
Thomas, J. H.,
Botstein, D.,
and Fink, G. R.
(1987)
Gene (Amst.)
60,
237-243
|
| 34.
|
Nasmyth, K. A.,
and Reed, S. I.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
2119-2123
|
| 35.
|
Carlson, M.,
and Botstein, D.
(1982)
Cell
28,
145-154
|
| 36.
|
Walsh, R. B.,
Kawasaki, G.,
and Fraenkel, D. G.
(1983)
J. Bacteriol.
154,
1002-1004
|
| 37.
|
Ozcan, S.,
and Johnston, M.
(1995)
Mol. Cell. Biol.
15,
1564-1572
|
| 38.
|
Frederick, D. L.,
and Tatchell, K.
(1996)
Mol. Cell. Biol.
16,
2922-2931
|
| 39.
|
Nehlin, J. O.,
and Ronne, H.
(1990)
EMBO J.
9,
2891-2898
|
| 40.
|
Lillie, S. H.,
and Pringle, J. R.
(1980)
J. Bacteriol.
143,
1384-1394
|
| 41.
|
Ghosh, S.,
and Roseman, S.
(1962)
Methods Enzymol.
5,
414-417
|
| 42.
|
Yocum, R. R.,
Hanley, S.,
West, R.,
and Ptashne, M.
(1984)
Mol. Cell. Biochem.
4,
1985-1988
|
| 43.
|
Ng, R.,
and Abelson, J.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
3912-3916
|
| 44.
|
Stuart, J. S.,
Frederick, D. L.,
Varner, C. M.,
and Tatchell, K.
(1994)
Mol. Cell. Biol.
14,
896-905
|
| 45.
|
Baker, S. H.,
Frederick, D. L.,
Bloecher, A.,
and Tatchell, K.
(1997)
Genetics
145,
615-626
|
| 46.
|
Ramaswamy, N. T.,
Li, L.,
Khalil, M.,
and Cannon, J. F.
(1998)
Genetics
149,
57-72
|
| 47.
|
Sassoon, I.,
Severin, F. F.,
Andrews, P. D.,
Taba, M. R.,
Kaplan, K. B.,
Ashford, A. J.,
Stark, M. J. R.,
Sorger, P. K.,
and Hyman, A. A.
(1999)
Genes Dev.
13,
545-555
|
| 48.
|
Biggins, S.,
Severin, F. F.,
Bhalla, N.,
Sassoon, I.,
Hyman, A. A.,
and Murray, A. W.
(1999)
Genes Dev.
13,
532-544
|
| 49.
|
Liu, H.,
Krizek, J.,
and Bretscher, A.
(1992)
Genetics
132,
665-673
|
| 50.
|
Watzele, G.,
and Tanner, W.
(1989)
J. Biol. Chem.
264,
8753-8758
|
| 51.
|
Orlean, P.
(1997)
The Molecular Biology of the Yeast Saccharomyces
, Vol. 3
, pp. 229-262, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 52.
|
Cid, V. J.,
Duran, A.,
del Rey, F.,
Snyder, M. P.,
Nombela, C.,
and Sanchez, M.
(1995)
Microbiol. Rev.
59,
345-386
|
| 53.
|
Levin, D. E.,
and Errede, B.
(1995)
Curr. Opin. Cell Biol.
7,
197-202
|
| 54.
|
Kamada, Y.,
Qadota, H.,
Python, C. P.,
Anraku, Y.,
Ohya, Y.,
and Levin, D. E.
(1996)
J. Biol. Chem.
271,
9193-9195
|
| 55.
|
Nonaka, H.,
Tanaka, K.,
Hirano, H.,
Fujiwara, T.,
Kohno, H.,
Umikawa, M.,
Mino, A.,
and Takai, Y.
(1995)
EMBO J.
14,
5931-5938
|
| 56.
|
Gustin, M. C.,
Albertyn, J.,
Alexander, M.,
and Davenport, K.
(1998)
Microbiol. Mol. Biol. Rev.
62,
1264-1300
|
| 57.
|
Posas, F.,
Camps, M.,
and Ario, J.
(1995)
J. Biol. Chem.
270,
13036-13041
|
| 58.
|
Hung, W.,
Olson, K. A.,
Breitkreutz, A.,
and Sadowski, I.
(1997)
Eur. J. Biochem.
245,
241-251
|
| 59.
|
Kuo, M. H.,
Nadeau, E. T.,
and Grayhack, E. J.
(1997)
Mol. Cell. Biol.
17,
819-832
|
| 60.
|
Gancedo, J. M.
(1998)
Microbiol. Mol. Biol. Rev.
62,
334-361
|
| 61.
|
Endo, S.,
Connor, J. H.,
Forney, B.,
Zhang, L.,
Ingebritsen, T. S.,
Lee, E. Y. C.,
and Shenolikar, S.
(1997)
Biochemistry
36,
6986-6992
|
| 62.
|
Kwon, Y. G.,
Huang, H. B.,
Desdouits, F.,
Girault, J. A.,
Greengard, P.,
and Nairn, A. C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3536-3541
|
| 63.
|
Zhao, S.,
and Lee, E. Y. C.
(1997)
J. Biol. Chem.
272,
28368-28372
|
| 64.
|
Goldberg, J.,
Huang, H.-B.,
Kwon, Y.-G.,
Greengard, P.,
Nairn, A. C.,
and Kuriyan, J.
(1995)
Nature
376,
745-753
|
| 65.
|
Thevelein, J. M.,
and de Winde, J. H.
(1999)
Mol. Microbiol.
33,
904-918
|
| 66.
|
Cameron, S.,
Levin, L.,
Zoller, M.,
and Wigler, M.
(1988)
Cell.
53,
555-566
|
| 67.
|
Milewski, S.,
Kuszczak, D.,
Jedrzejczak, R.,
Smith, R. J.,
Brown, A. J. P.,
and Gooday, G. W.
(1999)
J. Biol. Chem.
274,
4000-4008
|
| 68.
|
Bruhn, L.,
and Sprague, G. F.
(1994)
Mol. Cell. Biol.
14,
2534-2544
|
| 69.
|
Althoefer, H.,
Schleiffer, A.,
Wassmann, K.,
Nordheim, A.,
and Ammerer, G.
(1995)
Mol. Cell. Biol.
15,
5917-5928
|
| 70.
|
McInerny, C. J.,
Partridge, J. F.,
Mikesell, G. E.,
Creemer, D. P.,
and Breeden, L. L.
(1997)
Genes Dev.
11,
1277-1288
|
| 71.
|
Spellman, P. T.,
Sherlock, G.,
Zhang, M. Q.,
Iyer, V. R.,
Anders, K.,
Eisen, M. B.,
Brown, P. O.,
Botstein, D.,
and Futcher, B.
(1998)
Mol. Biol. Cell
9,
3273-3297
|
| 72.
|
Zhao, C.,
Jung, U. S.,
Garrett-Engele, P.,
Roe, T.,
Cyert, M. S.,
and Levin, D. E.
(1998)
Mol. Cell. Biol.
18,
1013-1022
|
| 73.
|
Dodou, E.,
and Treisman, R.
(1997)
Mol. Cell. Biol.
17,
1848-1859
|
| 74.
|
Fassler, J. S.,
Gray, W. M.,
Malone, C. L.,
Tao, W.,
Lin, H.,
and Deschenes, R. J.
(1997)
J. Biol. Chem.
272,
13365-13371
|
| 75.
|
Yu, G.,
Deschenes, R. J.,
and Fassler, J. S.
(1995)
J. Biol. Chem.
270,
8739-8743
|
| 76.
|
Shirra, M. K.,
and Arndt, K. M.
(1999)
Genetics
152,
73-87
|
| 77.
|
Ouyang, Q.,
Ruiz-Noriega, M.,
and Henry, S. A.
(1999)
Genetics
152,
89-100
|
| 78.
|
Dombek, K. M.,
Voronkova, V.,
Raney, A.,
and Young, E. T.
(1999)
Mol. Cell. Biol.
19,
6029-6040
|
| 79.
|
Lin, J. T.,
and Lis, J. T.
(1999)
Mol. Cell. Biol.
19,
3237-3245
|
| 80.
|
Bortvin, A.,
and Winston, F.
(1996)
Science
272,
1473-1476
|
| 81.
|
Hartzog, G. A.,
Wada, T.,
Handa, H.,
and Winston, F.
(1998)
Genes Dev.
12,
357-369
|
| 82.
|
Sikorski, R. S.,
and Hieter, P.
(1989)
Genetics
122,
19-27
|
| 83.
|
Christianson, T. W.,
Sikorski, R. S.,
Dante, M.,
Shero, J. H.,
and Hieter, P.
(1992)
Gene (Amst.)
110,
119-122
|
| 84. |